Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks. Medications used to treat MS, while modestly effective, can have side effects and be poorly tolerated. Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally with rates varying widely in different regions and among different populations. That year about 18,900 people died from MS, up from 12,000 in 1990
40% pf patients receive IFNβ -(Avonex, Rebif, Betaseron) – 50% respond.
Genefron Diagnostic Kit:
IFR FR 100 PDK (MS patients, Types: RR -relapsing remitting or SP- secondary progressive) – Used for predicting response to Interferon β based drug families. Biomarkers measurements combined with Genefron’s mathematical algorithm, exhibit 95% accuracy prediction. The random accuracy\respond rate is ~50%.
Retrospective prediction results of 25 MS patients (X-axis) response to IFNβ treatment using the genes of IFR 100 test. Two blood samples were drawn at T=0 and T=24h after treatment and expression levels were measured. Red bars – dynamic gene expression (difference between gene expression before and after IFN treatment measured in lo2TC). Blue bars – difference in relapse episodes before treatment and during the treatment.
One data set of our prospective clinical trial prediction results of MS patients (X-axis) treated by IFNβ. Our biomarkers level has been measured (Y axis log2TC) – Red bars- non-responders, Green bars- responders. Solid fill confirmed prediction by clinical parameters subject 312 is a borderline case.